[ad_1]
Hacettepe University School of Medicine, Head of the Department of Pediatric Infectious Diseases. Dr. Mehmet Ceyhan and Hacettepe University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology Faculty member Prof. Dr. Murat Akova evaluated DHA’s proposal to suspend the use of the coronavirus vaccine produced by AstraZeneca in 23 countries under suspected of causing blood clotting worldwide, and of continuing to use the WHO vaccine, stating that the benefits of the vaccine outweigh its harms. Saying that the vaccine is different from the drug because it is applied to a large number of healthy people, Ceyhan said: “In such applications, events that occur for reasons unrelated to the vaccine attract the attention of people who are vaccinated. one case, you have to suspend the vaccination applications until you are sure. “
‘WHO’S STATEMENT IS NOT ACCEPTABLE’
Teacher. Dr. Regarding the statement made by the WHO regarding the AstraZeneca vaccine, Ceyhan made a statement that said, “Use it instead of benefit.” This is not an acceptable situation in the vaccine. Serious side effects are not accepted in the vaccine, since millions of healthy people. Therefore, it is necessary to be absolutely sure. In the first evaluations it was observed that especially this intravascular coagulation event is greater than the number that is believed to be due to the vaccine. Intravenous clotting is not a situation that has been shown with the vaccine; But it is a situation that can be caused by hundreds of different diseases. and it is more common in the age group where the vaccine is administered. This must be supported with autopsies on the deceased. and studies on the presence and absence of the diseases that cause it. As a general rule, vaccination studies are suspended until they are supported, ”he said.
‘I DON’T THINK YOU CAN GO WITH THE VACCINE’
Teacher. In stating that he does not believe that clotting may be related to the vaccine, Ceyhan said that “vector vaccines similar to the AstraZeneca vaccine are used, a similar situation has not been observed. The vaccine became the second most used vaccine although it was introduced late. ” There were problems with the effectiveness of AstraZeneca. Report very different results. “It seems that its efficacy is somewhat less than mRNA vaccines, but many countries have received it from it, as it can prevent particularly serious diseases, as in other vaccines,” he said. saying.
AKOVA: YOU NEED MORE DATA
Teacher. Stating that this vaccination continues in England, Dr. Murat Akova said: “Until now, around 17 million doses of this vaccine have been manufactured and 11 million doses of this vaccine have been manufactured in England. In many countries around the world, in This vaccine actually exists. But the side effects of clotting and bleeding. The main thing here is that so far 1.6 million doses have been administered in Germany, and within these 1.6 million doses, a disorder has arisen very rare, which we call coagulation in the cerebral veins. that this condition is 4-5 times higher than normal after vaccination. But there is no consensus on this issue. Experts in England say this figure is acceptable. but still Thus, this situation must be evaluated. This is, of course, a serious situation. I have died and it is usually people under 50 years of age. When it comes to a death of this type in young people, they try to understand what the situation is in young people. countries. ” You need to collect some more data, “he said.
‘EFFICIENCY AROUND 80 PERCENT’
Stating that AstraZeneca is a vaccine that is around 80 percent efficient, can be easily produced, and can be stored at normal refrigerator temperature, Prof. Akova noted the following:
“There was a problem in the first study of this vaccine. When it was given 21 days apart and if you gave the 2 vaccines as a full dose, the efficacy of the vaccine was found to be about 50 percent low. The reason is of this is the ‘adenovirus’ used in this vaccine, which normally causes upper respiratory infection. And it is not the human adenovirus that causes a harmless infection, but the use of chimpanzee adenovirus as a carrier. Therefore, the range dose of this vaccine has already been opened in England and is administered 3 months apart. On the other hand, there are serious difficulties in accessing vaccines in the world, so the loss of a vaccine so easy to produce and in excess can cause serious difficulties in the fight against the pandemic. It believes that its balance is greater “.
